BG105736A - 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors - Google Patents

2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Info

Publication number
BG105736A
BG105736A BG105736A BG10573601A BG105736A BG 105736 A BG105736 A BG 105736A BG 105736 A BG105736 A BG 105736A BG 10573601 A BG10573601 A BG 10573601A BG 105736 A BG105736 A BG 105736A
Authority
BG
Bulgaria
Prior art keywords
matrix metalloproteinase
benzodiasepine
tetrahydro
hydroxamic acid
metalloproteinase inhibitors
Prior art date
Application number
BG105736A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jay Albright
Santos Efren Delos
Jeremy Levin
James Chen
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of BG105736A publication Critical patent/BG105736A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
BG105736A 1999-01-27 2001-07-26 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors BG105736A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908099A 1999-01-27 1999-01-27
PCT/US2000/001991 WO2000044730A1 (en) 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BG105736A true BG105736A (en) 2002-05-31

Family

ID=22900512

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105736A BG105736A (en) 1999-01-27 2001-07-26 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Country Status (25)

Country Link
EP (1) EP1147095B1 (xx)
JP (1) JP2002535392A (xx)
KR (1) KR20010101730A (xx)
CN (1) CN1197849C (xx)
AR (1) AR022423A1 (xx)
AT (1) ATE273288T1 (xx)
AU (1) AU767039B2 (xx)
BG (1) BG105736A (xx)
BR (1) BR0007759A (xx)
CA (1) CA2356267A1 (xx)
CZ (1) CZ20012637A3 (xx)
DE (1) DE60012883T2 (xx)
EA (1) EA200100809A1 (xx)
ES (1) ES2223470T3 (xx)
HU (1) HUP0105302A3 (xx)
ID (1) ID29046A (xx)
IL (1) IL144168A0 (xx)
NO (1) NO20013675L (xx)
NZ (1) NZ511885A (xx)
PL (1) PL349025A1 (xx)
PT (1) PT1147095E (xx)
SK (1) SK10422001A3 (xx)
TR (1) TR200102131T2 (xx)
WO (1) WO2000044730A1 (xx)
ZA (1) ZA200104321B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
WO2004014892A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
CA2572047C (en) * 2004-07-21 2014-04-08 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
CA2804918C (en) 2010-07-08 2018-03-06 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same
WO2012036257A1 (ja) * 2010-09-17 2012-03-22 国立大学法人東京大学 血小板の機能を維持するための組成物
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
EP4031160A4 (en) * 2019-09-19 2023-10-11 New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery STABILIZED C-FMS INTRACELLULAR FRAGMENTS (FICD) PROMOTE OSTEOCLAST DIFFERENTIATION AND ARTHRITIC BONE EROSION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0821671B1 (en) * 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
PL186869B1 (pl) * 1995-11-13 2004-03-31 Hoechst Ag Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP1095936B1 (en) * 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Intermediates useful for the preparation of metallproteinase inhibitors
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
KR20000035917A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,4-헤테로고리성 메탈로프로테아제 저해제
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
KR20010034406A (ko) * 1998-01-27 2001-04-25 아메리칸 사이아나미드 컴파니 매트릭스 메탈로프로테인아제 억제제로서의2,3,4,5-테트라하이드로-1ｈ-[1,4]-벤조디아제핀-3-하이드록삼산

Also Published As

Publication number Publication date
WO2000044730A1 (en) 2000-08-03
CN1197849C (zh) 2005-04-20
IL144168A0 (en) 2002-05-23
DE60012883T2 (de) 2005-08-25
EP1147095B1 (en) 2004-08-11
AU767039B2 (en) 2003-10-30
EA200100809A1 (ru) 2002-02-28
HUP0105302A2 (hu) 2002-07-29
SK10422001A3 (sk) 2002-09-10
EP1147095A1 (en) 2001-10-24
ATE273288T1 (de) 2004-08-15
NZ511885A (en) 2003-06-30
ID29046A (id) 2001-07-26
PL349025A1 (en) 2002-07-01
ZA200104321B (en) 2002-08-26
CN1337952A (zh) 2002-02-27
AR022423A1 (es) 2002-09-04
JP2002535392A (ja) 2002-10-22
DE60012883D1 (de) 2004-09-16
TR200102131T2 (tr) 2001-12-21
BR0007759A (pt) 2001-11-13
NO20013675L (no) 2001-09-21
NO20013675D0 (no) 2001-07-26
HUP0105302A3 (en) 2002-09-30
CZ20012637A3 (cs) 2002-04-17
AU3216000A (en) 2000-08-18
ES2223470T3 (es) 2005-03-01
PT1147095E (pt) 2004-12-31
CA2356267A1 (en) 2000-08-03
KR20010101730A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
BR0010598A (pt) Azoles substituìdos
WO1996040745A3 (en) Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
PT2261335T (pt) Composições e métodos para aumentar a mineralização óssea
UA72910C2 (uk) АЦЕТИЛЕНОВІ, ОСНОВАНІ НА <font face="Symbol">a</font>-АМІНОКИСЛОТАХ, ПОХІДНІ СУЛЬФОНАМІДІВ ГІДРОКСАМОВИХ КИСЛОТ, ЯКІ ІНГІБУЮТЬ TACE, СПОСІБ ЇХ ОДЕРЖАННЯ (ВАРІАНТИ), ПРОМІЖНА СПОЛУКА (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПАТОЛОГІЧНИХ ЗМІН, ПОВ'ЯЗАНИХ З УЧАСТЮ ТАСЕ, І ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
MXPA04000622A (es) Pirazolilcarboxanilidas como funguicidas.
GR3029449T3 (en) (e)-20(22)-dehydrovitamin d compounds
MX9706069A (es) Nuevos inhibidores de la trombina.
BR0214805A (pt) Lama viscosa de alta perda de fluido solúvel em ácido para circulação perdida
DK1149092T3 (da) 4- og 5-alkynyloxindoler og 4- og 5-alkenyloxindoler
AU6276700A (en) Liquid-crystalline medium
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
BR9809429A (pt) Diazepinoindolonas inibidoras de fosfodiesterase 4
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
ATE280152T1 (de) Acetylenische sulfonamid-thiol-tace-inhibitoren
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
GB2324528A (en) Cytostatic hydroxamic acid derivatives
RS88704A (xx) Derivati acil-3-karboksifenil- karbamida, postupak za njihovu proizvodnju i njihova primena
GB9923710D0 (en) Chemical compounds
PT1144369E (pt) Acidos hidroxamicos de arilsulfonamidas acetilenicas e de amidas de acido fosfinico acetilenicas inibidores de tace
CA2262769A1 (en) Low viscosity, high solids content slurry
EA200100808A1 (ru) ГИДРОКСАМОВЫЕ КИСЛОТЫ НА ОСНОВЕ АЦЕТИЛЕНОВОГО b-СУЛЬФОНАМИДО И АМИДА ФОСФИНОВОЙ КИСЛОТЫ, КАК ИНГИБИТОРЫ TACE
AU2002322396A1 (en) 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists